Uniqure NV
NASDAQ:QURE
Uniqure NV
NASDAQ:QURE
Price:
15.5815
USD
-2.25%
Market Cap:
$959.8m
Relative Value
The Relative Value of one
QURE
stock under the Base Case scenario is
8.4012
USD.
Compared to the current market price of 15.5815 USD,
Uniqure NV
is
Overvalued by 46%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
QURE
Relative Value
Base Case
8.4012
USD
Overvaluation 46%
Multiples Across Competitors
QURE Competitors Multiples
Uniqure NV Competitors
Uniqure NV Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NL |
|
Uniqure NV
NASDAQ:QURE
|
985.5m USD | 60.3 | -4.9 | -5.1 | -4.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
392.1B USD | 6.4 | 93.8 | 15.4 | 21.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
195.2B USD | 5.3 | 25.3 | 14.6 | 14.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.3B USD | 6.1 | 21.1 | 13.2 | 16.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.3B USD | 9.8 | 29.9 | 22.5 | 23.5 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.2B USD | 5.6 | 17.8 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.1B AUD | 3.1 | 34.6 | 11.4 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR | 10.8 | 34.6 | 37.5 | 38.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
